The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection

References

• Ploug M, Rønne E, Behrendt N, et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991;266(3):1926–1933.
   PubMed Web of Science ®Google Scholar
• Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3–4):157–172.
   PubMed Web of Science ®Google Scholar
• De Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24(1):13–39.
   PubMed Web of Science ®Google Scholar
• Estreicher A, Mühlhauser J, Carpentier JL, et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990;111(2):783–792.
   PubMed Web of Science ®Google Scholar
• Florquin S, van den Berg JG, Olszyna DP, et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int. 2001;59(6):2054–2061.
   PubMed Web of Science ®Google Scholar
• Grøndahl-Hansen J, Lund LR, Ralfkiaer E, et al. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J InvestDermatol. 1988;90:790–795.
   Web of Science ®Google Scholar
• Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31(8):1679–1685.
   PubMed Web of Science ®Google Scholar
• Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45:1–66.
   PubMedGoogle Scholar
• Armstrong DG, Lipsky BA. Diabetic foot infections: stepwise medical and surgical management. Int Wound J. 2004;1(2):123–132.
   PubMedGoogle Scholar
• Mavrogenis AF, Megaloikonomos PD, Antoniadou T, et al. Current concepts for the evaluation and management of diabetic foot ulcers. EFORT Open Rev. 2018;3(9):513–525.
   PubMed Web of Science ®Google Scholar
• Özkan Y, Çolak R, Demirdağ K, et al. Retrospective evaluation of 142 cases with diabetic foot syndrome. Turkiye Klin J Endocrinol. 2004;2:191–195.
   Google Scholar
• Lavery LA, Armstrong DG, Wunderlich RP, et al. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29(6):1288–1293.
   PubMed Web of Science ®Google Scholar
• Alavi A, Sibbald RG, Mayer D, Goodman L, et al. Diabetic foot ulcers: part I. Pathophysiology and prevention. J Am Acad Dermatol. 2014;70(1):e1–18.
   PubMed Web of Science ®Google Scholar
• Richard J-L, Sotto A, Lavigne J-P. New insights in diabetic foot infection. WJD. 2011;2(2):24–32.
   Google Scholar
• Jeandrot A, Richard J-L, Combescure C, et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia. 2008;51(2):347–352.
   PubMed Web of Science ®Google Scholar
• Mizukami IF, Faulkner NE, Gyetko MR, et al. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood. 1995;86(1):203–211.
   PubMed Web of Science ®Google Scholar
• Speth C, Pichler I, Stöckl G, et al. Urokinase plasminogen activator receptor (uPAR; CD87) expression on monocytic cells and T cells is modulated by HIV-1 infection. Immunobiology. 1998;199(1):152–162.
   PubMed Web of Science ®Google Scholar
• Galliera E, Drago L, Marazzi MG, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: correlation with inflammatory cytokines. Clin Chim Acta. 2015;441:23–28.
   PubMed Web of Science ®Google Scholar
• Wrotek A, Jackowska T, Pawlik K. Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children. Adv Exp Med Biol. 2015;835:1–7.
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Piironen T, Høyer-Hansen G, et al. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(1):23–31.
   PubMed Web of Science ®Google Scholar
• Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38(9):1418–1428.
   PubMed Web of Science ®Google Scholar
• Donadello K, Scolletta S, Covajes C, et al. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10(1):2.
   PubMed Web of Science ®Google Scholar
• Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15(1):R63.
   PubMed Web of Science ®Google Scholar
• Kofoed K, Eugen-Olsen J, Petersen J, et al. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis. 2008;27(5):375–383.
   PubMed Web of Science ®Google Scholar
• Demiraslan H, Karaca Z, Bayram F. Diabetic foot ulcers. Tükiye Klin. J Endocrin Spec Top. 2008;1:44–55.
   Google Scholar
• Wittenhagen P, Kronborg G, Weis N, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect. 2004;10(5):409–415.
   PubMed Web of Science ®Google Scholar